SG Americas Securities’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-17,384
| Closed | -$825K | – | 3585 |
|
|
2025
Q3 | $825K | Buy |
17,384
+12,039
| +225% | +$583K | ﹤0.01% | 1654 |
|
|
2025
Q2 | $285K | Sell |
5,345
-1,150,442
| -100% | -$52.3M | ﹤0.01% | 2045 |
|
|
2025
Q1 | $46.8M | Buy |
1,155,787
+557,794
| +93% | +$23.6M | 0.15% | 93 |
|
|
2024
Q4 | $16.6M | Buy |
597,993
+583,486
| +4,022% | +$17.7M | 0.07% | 155 |
|
|
2024
Q3 | $416K | Sell |
14,507
-10
| -0.1% | -$261 | ﹤0.01% | 1852 |
|
|
2024
Q2 | $341K | Buy |
14,517
+9,532
| +191% | +$204K | ﹤0.01% | 1894 |
|
|
2024
Q1 | $126K | Sell |
4,985
-2,503
| -33% | -$60.1K | ﹤0.01% | 2357 |
|
|
2023
Q4 | $175K | Sell |
7,488
-11,646
| -61% | -$230K | ﹤0.01% | 2284 |
|
|
2023
Q3 | $968K | Buy |
19,134
+11,148
| +140% | +$519K | 0.01% | 1292 |
|
|
2023
Q2 | $373K | Buy |
7,986
+1,498
| +23% | +$68.6K | ﹤0.01% | 1533 |
|
|
2023
Q1 | $248K | Buy |
6,488
+637
| +11% | +$28.4K | ﹤0.01% | 2261 |
|
|
2022
Q4 | $321K | Sell |
5,851
-10,250
| -64% | -$439K | ﹤0.01% | 1870 |
|
|
2022
Q3 | $548K | Sell |
16,101
-5,314
| -25% | -$81.3K | 0.01% | 1474 |
|
|
2022
Q2 | $202K | Buy |
+21,415
| New | +$223K | ﹤0.01% | 2665 |
|
|
2021
Q4 | – | Sell |
-52,255
| Closed | -$1.17M | – | 3347 |
|
|
2021
Q3 | $1.17M | Buy |
52,255
+28,742
| +122% | +$651K | 0.01% | 1769 |
|
|
2021
Q2 | $583K | Sell |
23,513
-451
| -2% | -$12.7K | ﹤0.01% | 1873 |
|
|
2021
Q1 | $695K | Buy |
+23,964
| New | +$725K | ﹤0.01% | 1781 |
|
|
2020
Q3 | – | Sell |
-6,087
| Closed | -$152K | – | 2662 |
|
|
2020
Q2 | $152K | Buy |
+6,087
| New | +$139K | ﹤0.01% | 3085 |
|
|
2019
Q3 | – | Sell |
-10,000
| Closed | -$192K | – | 2979 |
|
|
2019
Q2 | $192K | Buy |
+10,000
| New | +$190K | ﹤0.01% | 2432 |
|
Other funds holding AKRO
SG Americas Securities's AKRO Position: Q4 2025 in Review
SG Americas Securities sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 17,384 shares — an estimated $825K sold.
SG Americas Securities first reported a position in AKRO in Q2 2019 and held it in 19 quarters. The position peaked at $46.8M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- SG Americas Securities reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- SG Americas Securities sold 17,384 Akero Therapeutics shares in Q4 2025, an estimated $825K.
- SG Americas Securities first reported a position in Akero Therapeutics in Q2 2019 and held it in 19 quarters.
- SG Americas Securities's Akero Therapeutics position peaked at $46.8M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.